Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

KNKarun NeupaneCWCorbin WrightJWJunmin Whiting

Discussion

Loading...

Member takes

Overview

Observational analysis reports 79% overall response rate in RRMM patients treated with talquetamab, indicating real-world efficacy and manageable toxicities.

Key Points

  • Talquetamab achieved an overall response rate of 79% among patients, with early responses observable shortly after treatment begins.
  • The median progression-free survival was 8.4 months, highlighting the therapy's potential durability in relapsed/refractory multiple myeloma patients.
  • Statistical analysis utilized logistic regression and Kaplan-Meier methods to assess outcomes based on multiple patient characteristics.
  • High-risk cytogenetics and prior exposure to bispecific antibodies were associated with reduced overall and progression-free survival, indicating treatment challenges.

Cite This Study

Neupane et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da94https://doi.org/10.1182/blood-2025-4051
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs2025
  2. 2Talquetamab outcomes from practice outside of clinical trials: The bital study2025
  3. 3Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis2025
  4. 4Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials2025 · 1 citations
  5. 5Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma2025 · 3 citations